Dengue cure: S'pore researchers move to next phase
SingHealth and Duke-NUS in exclusive licensing deal with US firm 60° Pharmaceuticals
[SINGAPORE] Even as the world's first dengue vaccine is set to hit Singapore shores next year, reseachers here are one step closer to finding the first antiviral drug that treats the illness.
Researchers from the Singapore General Hospital and Duke-NUS Graduate Medical School completed a study called CELADEN last year that found Celgosivir, a medicine derived from the seeds of the Moreton Bay Chestnut trees, to be safe for dengue patients.
The S$1.6 million clinical trial of the drug was conducted from July 2012 to March 2013 on 50 dengue patients.
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
New Articles
Singapore top recipient of Q1 cross-border investments in Apac: Knight Frank
Dasin Retail Trust’s trustee-manager chairman, directors deny allegations of misconduct
Keppel Infrastructure Trust posts 29.1% lower Q1 distributable income
Bitcoin faces worst month since FTX crash with ETF demand cooling
AIA launches wealth centre targeting high-net-worth clients
Prudential’s Q1 new business profit down 2% at S$743 million